Breast cancer patients who take carvedilol with trastuzumab have less heart damage
Patients with non-metastatic HER2-positive breast cancer who take carvedilol at the same time as trastuzumab have less heart damage, according to a study presented Dec. 5, 2018 at EuroEcho-Imaging 2018. These findings indicate that carvedilol may be an effective way to prevent the heart damage caused by trastuzumab treatment.
To continue reading this article
Continue reading your article with a eMediNexus account.